Deep Medicine Acquisition Corp. Confirms Funding to Extend Period to Consummate Initial Business Combination
20 Octubre 2022 - 3:30PM
Deep Medicine Acquisition Corp. (Nasdaq: DMAQ) (the “Company”),
announced today that an aggregate of $1,265,000 has been deposited
into the Company’s trust account for its public shareholders,
representing $0.10 per public share, which enables the Company to
extend the period of time it has to consummate its initial business
combination by three months from October 29, 2022 to January 29,
2023 (the “Extension”). The Extension is the first of up to two
three-month extensions permitted under the Company’s governing
documents.
About Deep Medicine
Acquisition Corp.
DMAQ is a special purpose acquisition company
formed for the purpose of entering into a merger, capital stock
exchange, asset acquisition, stock purchase, reorganization or
other similar business combination with one or more businesses or
entities. DMAQ began trading on the Nasdaq in October 2021, and its
common stock and rights are traded under the ticker symbols DMAQ
and DMAQR, respectively.
Cautionary Note Regarding
Forward-Looking Statements
This press release may include, and oral
statements made from time to time by representatives of the Company
may include, “forward-looking statements” within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. Statements
regarding possible business combinations and the financing thereof,
and related matters, as well as all other statements other than
statements of historical fact included in this press release are
forward-looking statements. When used in this press release, words
such as “anticipate,” “believe,” “continue,” “could,” “estimate,”
“expect,” “intend,” “may,” “might,” “plan,” “possible,”
“potential,” “predict,” “project,” “should,” “would” and similar
expressions, as they relate to us or our management team, identify
forward-looking statements. Such forward-looking statements are
based on the beliefs of management, as well as assumptions made by,
and information currently available to, the Company’s management.
Actual results could differ materially from those contemplated by
the forward-looking statements as a result of certain factors
detailed in the Company’s filings with the Securities and Exchange
Commission (“SEC”). All subsequent written or oral forward-looking
statements attributable to us or persons acting on our behalf are
qualified in their entirety by this paragraph. Forward-looking
statements are subject to numerous conditions, many of which are
beyond the control of the Company, including those set forth in the
Risk Factors section of the Company’s registration statement and
prospectus for the Company’s initial public offering filed with the
SEC. The Company undertakes no obligation to update these
statements for revisions or changes after the date of this release,
except as required by law.
Contact
Humphrey Polanen, Chief Executive OfficerDeep
Medicine Acquisition Corp.595 Madison Avenue, 12th FloorNew York,
NY 10017ir@dmaq-spac.comTelephone: (917) 289-2776
Deep Medicine Acquisition (NASDAQ:DMAQ)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Deep Medicine Acquisition (NASDAQ:DMAQ)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024